Can tigecycline be linked to elevated transaminases?

Can tigecycline raise liver enzymes?

Tigecycline has been associated with increases in liver enzymes, including alanine aminotransferase and aspartate aminotransferase, during clinical use. These elevations are generally mild to moderate and reversible after the drug is stopped. Liver function monitoring is advised while patients receive the antibiotic.

Why do transaminases rise with tigecycline?

The mechanism is not fully understood. Tigecycline undergoes hepatic metabolism and biliary excretion, which may place stress on hepatocytes. Case reports suggest direct hepatocyte injury or cholestatic patterns can appear within days to weeks of starting therapy. Pre-existing liver disease or concurrent hepatotoxic drugs may increase risk.

How common are these liver enzyme changes?

Elevated transaminases occurred in roughly 3–5 % of patients in Phase 3 trials. Post-marketing surveillance has recorded additional cases, some meeting criteria for drug-induced liver injury. Most reports resolve without long-term consequences once the drug is discontinued.

What should clinicians monitor?

Baseline liver-function tests are recommended, with repeat checks every few days during therapy and again after completion. Any rise above three times the upper limit of normal warrants consideration of dose adjustment or alternative antibiotics. Patients should be asked about symptoms such as fatigue, jaundice, or dark urine.

Can tigecycline still be used safely in patients with liver impairment?

Dose adjustment is not required for mild or moderate hepatic impairment. In severe impairment (Child-Pugh C), the maintenance dose is reduced to 25 mg every 12 hours after the initial 100 mg load. Close laboratory follow-up is essential in this population.

How does tigecycline compare with other tetracyclines regarding liver safety?

Minocycline and doxycycline have longer track records of hepatotoxicity, often linked to autoimmune hepatitis patterns. Tigecycline’s shorter treatment courses may limit cumulative exposure, but direct head-to-head studies are lacking. Choice among these agents depends on the infection, local resistance patterns, and individual patient risk factors.

When do patents on tigecycline expire?

The key U.S. composition-of-matter patent for tigecycline expired in 2015, yet formulation and method-of-use patents extend market exclusivity for certain indications into the mid-2020s. DrugPatentWatch.com tracks the remaining patent family and lists tentative generic approvals expected after 2025.